Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Favorable Outcomes of Bridging Glofitamab Prior to anti-CD19 CAR-T cell Therapy in patients with non-Hodgkin lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

YZYinqiang ZhangLLLin Liu

Discussion

Loading...

Member takes

Overview

Observational study shows high response rates of glofitamab bridging therapy in non-Hodgkin lymphoma patients, suggesting improved treatment outcomes.

Key Points

  • To evaluate the efficacy and safety of glofitamab as a bridging therapy prior to CAR-T cell treatment.
  • Conducted an observational study with patients having relapsed/refractory non-Hodgkin lymphoma.
  • Patients received obinutuzumab followed by glofitamab, with some receiving additional therapies like gemcitabine.
  • Response rates were assessed based on Lugano criteria, along with the monitoring of adverse events.
  • Overall response rate of 66.7% and complete metabolic response in 22.2% of patients after glofitamab bridging.
  • Cytokine release syndrome occurred in 70% of patients; most cases were grade 1.
  • CAR-T therapy resulted in a complete metabolic response in 80% of patients at day +30 post-infusion.

Cite This Study

Zhang et al. (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d6b7https://doi.org/10.1182/blood-2025-7261
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comprehensive analysis of bridging to CAR-T cell therapy in large B-cell lymphoma with conventional treatment or the CD3xCD20 bispecific antibody glofitamab2025
  2. 2Short-course glofitamab enables effective bridging to CAR-t therapy in B-NHL2025 · 1 citations
  3. 3Glofitamab based combined therapy as bridging therapy before stem cell transplants and CAR-T therapy in large B-cell lymphoma.2025 · 1 citations
  4. 4Glofitamab effectively bridging CD19-specific CAR T- cell therapy while maintaining safety in patients with refractory DLBCL2025
  5. 5Glofitamab in combination with CD19 CAR-T therapy for high-risk relapsed/refractory large B-cell lymphoma2025 · 1 citations